首頁 › 惰性多發性骨髓瘤 › 紐約州 › New York City
New York City, NY 的 惰性多發性骨髓瘤 臨床試驗
6 項針對 惰性多發性骨髓瘤 的研究正在 New York City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
招募中
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
招募中3 期
- Memorial Sloan Kettering Cancer Center, New York
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
招募中3 期
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
招募中2 期
- NYU Langone Health Perlmutter Cancer Center, New York
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
招募中
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
招募中觀察性研究
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
其他城市的 惰性多發性骨髓瘤 試驗
- Boston, MA6 項研究
- Atlanta, GA5 項研究
- Durham, NC3 項研究
- Salt Lake City, UT3 項研究
- Columbus, OH3 項研究
- Edison, NJ3 項研究
- Houston, TX3 項研究
- Denver, CO3 項研究
New York City 的其他研究
- 乳癌136 項研究
- 非小細胞肺癌121 項研究
- 癌症（所有類型）109 項研究
- 前列腺癌103 項研究
- 轉移性癌症93 項研究
- 大腸直腸癌78 項研究
- 卵巢癌69 項研究
- 肺癌60 項研究
- 多發性骨髓瘤60 項研究
- 胰臟癌60 項研究
- 子宮內膜癌52 項研究
- 急性髓系白血病51 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。